retatrutide type 2 diabetes More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase 🚨Breaking: Retatrutide's first Phase 3

After SELECT, the debate ended

Decision matrix Safety considerations researchers should know Both compounds are newer than established GLP-1 agonists , which means their long-term safety profiles are still being characterized

Originally developed for managing type 2 diabetes, these medications are now making headlines for their broader impact on weight, metabolic health and cardiovascular health

About this article Cite this article Stoicovy, R.A., Cora, N., Perez, A

Betsy Dovec, MD, FACS , says that it's reasonable to wonder if GLP-1 patches will hit the market soon

Unlike current single (GLP-1) and dual (GLP-1/GIP) agonist compounds like Semaglutide and Tirzepatide , Retatrutide is a triple agonist compound targeting three hormone receptors instead of only one or two: GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) GCG (glucagon receptor) According to a landmark clinical trial published in the New England Journal of Medicine , Retatrutide demonstrated significant weight reduction, up to 30%, in participants over a 48-week period, highlighting its potential as a next-generation metabolic peptide